In The News:
C. difficile Infection– Treatment On The Horizon
Summit Therapeutics PLC
The US patent and trademark office have granted a “composition of matter” patent.
It gives a period of exclusivity for ridinilazole in the United States until at least December 1, 2029, with the possibility of being extended.
It’s been a busy period for the firm and Glyn Edwards, Chief Executive said: “This new patent grant in one of our potential major commercial markets substantially strengthens our intellectual property estate protecting our novel CDI antibiotic ridinilazole and supports our efforts to maximize the potential of this promising compound.”
“We are focused on our CDI and DMD programmes and today’s news, combined with the recently announced expansion advancing of our PhaseOut DMD trial, highlights their continuing excellent progress as we seek to have a meaningful impact on the lives of patients living with these serious diseases.”
In a Phase 2 clinical trial, ridinilazole showed statistical superiority over vancomycin – the standard of care medicine – in rates of sustained clinical response, an endpoint that captures both initial cure and recurrence of the disease.
To read article in its entirety:
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.